Concepedia

Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein

Barbara E. Mahon, Jakub K. Simon, Marc‐Alain Widdowson, Mohamed Samai, Eric Rogier, Jennifer Legardy-Williams, Kenneth Liu, Jarad Schiffer, J. Lange, Carolynn DeByle,

The Journal of Infectious Diseases · 2021 · 16 citations · 22 references

DOIFull text

Open access

Abstract

Asymptomatic adults with or without malaria parasitemia had robust immune responses to rVSVΔG-ZEBOV-GP, persisting for 9-12 months. Responses in those with malaria parasitemia were somewhat lower.

References

22

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

Ana María Henao-Restrepo, Anton Camacho, Ira M. Longini et al. · The Lancet · 2016 · 1.1K citations · Full text

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

Steven J.M. Jones, Heinz Feldmann, Ute Ströher et al. · Nature Medicine · 2005 · 679 citations · Full text

, , +9

Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017

Laura Dwyer‐Lindgren, Michael A. Cork, Amber Sligar et al. · Nature · 2019 · 516 citations · Full text

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Sélidji Todagbé Agnandji, Angela Huttner, Madeleine E. Zinser et al. · New England Journal of Medicine · 2015 · 404 citations · Full text

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

Jason A. Regules, John H. Beigel, Kristopher Paolino et al. · New England Journal of Medicine · 2015 · 380 citations · Full text